Tamoxifen in the Management of Breast Cancer: A Case Presented in Multidisciplinary Session With Clinical Discussion and Decision-Making
Abstract
Background: Selective estrogen receptor modulators (SERMs) have been shown to reduce the risk of developing estrogen-positive breast cancer. Tamoxifen, a potent SERM, has been successfully administered as adjuvant therapy for breast cancer. However, uterine pathologic changes may develop due to the effect of tamoxifen as both an agonist and antagonist of estrogen on the uterus. Here, we discuss a case of breast cancer treated with tamoxifen to clarify one of the most important complications, namely, endometrial hyperplasia.
Case Presentation: A 51-year-old woman presented with left breast mass and axillary lymphadenopathy. Mammography showed a 26-mm spiculated mass consistent with invasive ductal carcinoma in core needle biopsy. Immunohistochemical analysis revealed that the tumor was ER- and PR-positive, HER2-negative, and P53-negative. Adjuvant chemotherapy was completed, and the patient was referred to undergo adjuvant radiotherapy (RT). After the completion of RT, treatment with tamoxifen was initiated at the recommended dose of 20 mg/day.
Questions: The questions are when to use tamoxifen as adjuvant therapy for breast cancer, How to follow the patient treated with tamoxifen, and when to discontinue tamoxifen therapy.
Conclusion: Use of tamoxifen for at least 5 years after diagnosis is a reasonable option for the prevention of breast cancer or its recurrence in high-risk patients. Premenopausal women on tamoxifen presenting with abnormal uterine bleeding must undergo transvaginal ultrasonography. For premenopausal women taking tamoxifen, irregular vaginal bleeding should be evaluated by hysteroscopy or uterine ultrasonography, and, if the etiology remains unclear, a biopsy should be done. There are no evidence-based recommendations for uterine malignancy screening in patients who take tamoxifen. Current recommendations are annual gynecologic examination and evaluation of any abnormal vaginal bleeding.
References
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827-34.
Daniel Y, Inbar M, Bar-Am A, Peyser MR, Lessing JB. The effects of tamoxifen treatment on the endometrium. Fertil Steril. 1996;65(6):1083-9.
Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988;48(4):812-5.
Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994;47(9):827-33.
Kim HS, Jeon YT, Kim YB. The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients. J Gynecol Oncol. 2008;19(4):256-60.
Hulka CA, Hall DA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. AJR Am J Roentgenol. 1993;160(4):809-12.
Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H, et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol. 1999;73(1):21-6.
van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343(8895):448-52.
Shushan A, Peretz T, Uziely B, Lewin A, Mor-Yosef S. Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol. 1996;174(1 Pt 1):141-4.
Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study G. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005;97(5):375-84.
Fung MF, Reid A, Faught W, Le T, Chenier C, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 2003;91(1):154-9.
Liedman R, Lindahl B, Andolf E, Willen R, Ingvar C, et al. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res. 2000;20(6C):4889-91.
National Comprehensive Cancer N. NCCN Guideline update: Breast Cancer Version 1.2004. J Natl Compr Canc Netw. 2004;2(3):183-4.
Chen. WY. Selective estrogen receptor modulator and aromatase inhibitors for breast cancer prevention. Up to date. 2018.
Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 1999;91(19):1654-62.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-16.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017;15(4):433-51.
Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol. 2000;18(20):3459-63.
The American college of Obstetricians and Gynecologists, ACOG Committee opinion, No 601, June 2014, Reaffirmed 2019.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-62.
Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280(17):1510-7.
Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, Gray R, Clarke M, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84.
committee on practice Bulletines-Gynecology. ACOG No.126; management of gynecologic issues in women with breast cancer. Obstet gynecol 2012; 119:666
Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, et al. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol. 2002;101(1):58-63.
Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, et al. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg. 2018;105(9):1098-106.
Korkmazer E, Solak N, Tokgoz VY. Assessment of thickened endometrium in tamoxifen therapy. Turk J Obstet Gynecol. 2014;11(4):215-8.
Gultekin IB, Imamoglu GI, Gultekin S, Yilmaz EA, Yilmaz Z, et al. Elastosonographic evaluation of endometrium in women using tamoxifen for breast cancer. Niger J Clin Pract. 2019;22(1):92-100.
Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, et al. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. AJR Am J Roentgenol. 1997;168(3):657-61.
Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging. 2008;8:135-45.
Authors
Copyright (c) 2019 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.
